SRNE — Sorrento Therapeutics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual cashflow statement for Sorrento Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2018 December 31st	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-213	-363	-314	-429	-578
Depreciation
Non-Cash Items	85.7	172	140	138	201
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	6	7.25	3.8	-2.79	69.6
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Cash from Operating Activities	-112	-173	-160	-282	-294
Capital Expenditures	-11.2	-28.5	-6.53	-8.87	-13.7
Purchase of Fixed Assets
Other Investing Cash Flow Items	-10	-9.69	-33.4	88.7	-14.9
Acquisition of Business
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-21.2	-38.2	-39.9	79.8	-28.5
Financing Cash Flow Items	-36.9	0	-55	—	0.426
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	326	78.9	174	181	312
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	193	-133	-24.3	-19.8	-13